U.S. markets close in 1 hour 30 minutes

Otonomy, Inc. (OTIC)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.1000+0.0300 (+1.45%)
As of 02:17PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Long-term KST

Long-term KST

Previous Close2.0700
Bid2.0900 x 1100
Ask2.1000 x 3100
Day's Range2.0100 - 2.1200
52 Week Range1.1400 - 2.5900
Avg. Volume142,401
Market Cap119.535M
Beta (5Y Monthly)1.66
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for OTIC

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Otonomy, Inc.
    Analyst Report: Eli Lilly and CompanyEli Lilly is a drug firm with a focus on neuroscience, endocrinology, oncology, and immunology. Lilly's key products include Alimta and Verzenio for cancer; Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.
    Fair Value
    Economic Moat
    4 months agoMorningstar
View more
  • Motley Fool

    Otonomy (OTIC) Q1 2022 Earnings Call Transcript

    Joining me on the call from Otonomy are Dr. David Weber, president and chief executive officer; and Paul Cayer, chief financial and business officer. Before I turn the call over to Dr. Weber, I would like to remind you that today's call will include forward-looking statements based on current expectations.

  • Benzinga

    Otonomy Hearing Loss Candidate Shows Clinical Benefit On Multiple Efficacy Endpoints

    Otonomy Inc (NASDAQ: OTIC) announced topline results from the Phase 2a clinical trial of OTO-413 in subjects with hearing loss. The trial demonstrated that a single intratympanic injection of 0.3 mg OTO-413 provided clinically meaningful treatment benefit versus placebo across multiple speech-in-noise (SIN) hearing tests and the Patient Global Impression of Change at consecutive time points (Days 57 and 85). 40% (8 of 20) of OTO-413 subjects demonstrated a clinically meaningful improvement on at

  • Simply Wall St.

    Here's What Otonomy, Inc.'s (NASDAQ:OTIC) Shareholder Ownership Structure Looks Like

    Every investor in Otonomy, Inc. ( NASDAQ:OTIC ) should be aware of the most powerful shareholder groups. Institutions...